vs
Side-by-side financial comparison of Merck & Co. (MRK) and Vale S.A. (VALE). Click either name above to swap in a different company.
Merck & Co. is the larger business by last-quarter revenue ($16.4B vs $8.8B, roughly 1.9× Vale S.A.). Vale S.A. runs the higher net margin — 24.3% vs 18.1%, a 6.2% gap on every dollar of revenue. On growth, Merck & Co. posted the faster year-over-year revenue change (5.0% vs -11.3%).
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
Vale, formerly Companhia Vale do Rio Doce, is a Brazilian multinational corporation engaged in metals and mining and one of the largest logistics operators in Brazil. Vale is the largest producer of iron ore and nickel in the world. It also produces manganese, ferroalloys, copper, bauxite, potash, kaolin, and cobalt; as of 2014 the company operated nine hydroelectricity plants, and a large network of railroads, ships, and ports used to transport its products.
MRK vs VALE — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.4B | $8.8B |
| Net Profit | $3.0B | $2.1B |
| Gross Margin | 66.2% | 30.9% |
| Operating Margin | 20.9% | 22.8% |
| Net Margin | 18.1% | 24.3% |
| Revenue YoY | 5.0% | -11.3% |
| Net Profit YoY | -20.8% | -22.9% |
| EPS (diluted) | $1.19 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.4B | — | ||
| Q3 25 | $17.3B | — | ||
| Q2 25 | $15.8B | $8.8B | ||
| Q1 25 | $15.5B | — | ||
| Q4 24 | $15.6B | — | ||
| Q3 24 | $16.7B | — | ||
| Q2 24 | $16.1B | $9.9B | ||
| Q1 24 | $15.8B | — |
| Q4 25 | $3.0B | — | ||
| Q3 25 | $5.8B | — | ||
| Q2 25 | $4.4B | $2.1B | ||
| Q1 25 | $5.1B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $5.5B | $2.8B | ||
| Q1 24 | $4.8B | — |
| Q4 25 | 66.2% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 77.5% | 30.9% | ||
| Q1 25 | 78.0% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 75.5% | — | ||
| Q2 24 | 76.8% | 36.0% | ||
| Q1 24 | 77.6% | — |
| Q4 25 | 20.9% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | 31.6% | 22.8% | ||
| Q1 25 | 38.0% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 24.6% | — | ||
| Q2 24 | 37.3% | 39.1% | ||
| Q1 24 | 35.9% | — |
| Q4 25 | 18.1% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 28.0% | 24.3% | ||
| Q1 25 | 32.7% | — | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 33.9% | 27.9% | ||
| Q1 24 | 30.2% | — |
| Q4 25 | $1.19 | — | ||
| Q3 25 | $2.32 | — | ||
| Q2 25 | $1.76 | $0.50 | ||
| Q1 25 | $2.01 | — | ||
| Q4 24 | $1.49 | — | ||
| Q3 24 | $1.24 | — | ||
| Q2 24 | $2.14 | $0.65 | ||
| Q1 24 | $1.87 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.6B | $5.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $52.6B | $40.5B |
| Total Assets | $136.9B | $90.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.6B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $8.6B | $5.5B | ||
| Q1 25 | $9.2B | — | ||
| Q4 24 | $13.7B | — | ||
| Q3 24 | $14.6B | — | ||
| Q2 24 | $11.4B | $6.5B | ||
| Q1 24 | $5.6B | — |
| Q4 25 | $52.6B | — | ||
| Q3 25 | $51.9B | — | ||
| Q2 25 | $49.0B | $40.5B | ||
| Q1 25 | $48.3B | — | ||
| Q4 24 | $46.3B | — | ||
| Q3 24 | $44.5B | — | ||
| Q2 24 | $43.6B | $38.4B | ||
| Q1 24 | $40.4B | — |
| Q4 25 | $136.9B | — | ||
| Q3 25 | $129.5B | — | ||
| Q2 25 | $117.5B | $90.4B | ||
| Q1 25 | $115.1B | — | ||
| Q4 24 | $117.1B | — | ||
| Q3 24 | $117.5B | — | ||
| Q2 24 | $112.6B | $86.6B | ||
| Q1 24 | $105.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9B | — |
| Free Cash FlowOCF − Capex | $1.8B | — |
| FCF MarginFCF / Revenue | 11.1% | — |
| Capex IntensityCapex / Revenue | 6.3% | — |
| Cash ConversionOCF / Net Profit | 0.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | — | ||
| Q3 25 | $7.8B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $9.3B | — | ||
| Q2 24 | $5.6B | — | ||
| Q1 24 | $3.1B | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $6.8B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 39.6% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 7.5% | — | ||
| Q4 24 | 16.1% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 30.1% | — | ||
| Q1 24 | 14.1% | — |
| Q4 25 | 6.3% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 8.6% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 4.9% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.92× | — | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 0.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
VALE
Segment breakdown not available.
